Pfizer’s new orodispersible migraine tablet receives definitive registration from Anvisa in Brazil

Agência Nacional of Vigilância Sanitária (Anvisa) officially approved the registration of the drug Nurtec ODT on the national market. The regulatory decision took place on Monday (25), through publication on Diário Oficial of União. The pharmaceutical product, developed and manufactured by Pfizer, has rimegepant hemisulfate sesquihydrate as its active ingredient. The substance acts directly on the central nervous system and offers a pharmacological approach aimed at the acute treatment and prevention of migraine attacks. The federal agency’s approval represents a significant change in the therapeutic options available to Brazilian patients.
The central innovation of the new drug lies in its dual clinical functionality. The medication belongs to the class of CGRP antagonists and works to block specific proteins responsible for the inflammatory cascade. Diferentemente of most modern preventive treatments already marketed in Brasil, which require administration via injection, the Pfizer product is in an orodispersible tablet format. The technology allows the pill to dissolve quickly in the patient’s mouth. Practicality eliminates the need to drink water during intense crises and facilitates adherence to ongoing treatment.
Mecanismo action and blockade of pain-associated protein
The functioning of rimegepant is based on the direct inhibition of the peptide related to the calcitonin gene, known in medical circles by the acronym CGRP. Esta protein plays a key role in the pathophysiology of migraine. Durante a crisis, CGRP levels increase considerably in the trigeminal nervous system. Excess of the substance causes neurogenic inflammation and transmits intense pain signals to the brain. Blocking this receptor interrupts the pain cycle before it reaches its maximum peak.
Common analgesics and non-steroidal anti-inflammatory drugs act systemically and generically in the human body. The new tablet acts in a highly specific way on the neurological pathways of headache. Molecular specificity reduces the burden on organs such as the liver and stomach. Pacientes with chronic conditions often develop tolerance or suffer from the rebound effect caused by excessive use of traditional analgesics. The introduction of targeted therapy minimizes these risks associated with prolonged self-medication.
Neurologist Sara Casagrande, member of Sociedade Brasileira, Cefaleias and International Headache Society, assesses the impact of the new development. The specialist points out that the main difference of the medication is precisely the unprecedented combination of acute treatment and prophylaxis in a single oral presentation. The flexibility of use allows the doctor to adjust the prescription according to the frequency and intensity of each individual’s crises. The oral route also reduces the anxiety of patients who have an aversion to needles and periodic injections.
Cardiovascular Segurança and clinical indication of Nurtec ODT
One of the biggest obstacles in conventional migraine treatment involves the cardiovascular restrictions of triptan class medications. Older remedies work by inducing vasoconstriction, a narrowing of blood vessels that helps relieve throbbing head pain. The mechanism, however, presents severe risks for people with a history of hypertension, heart attack or stroke. Rimegepant does not cause vasoconstriction at any stage of its metabolism.
The absence of a vasoconstrictor effect drastically increases the safety of the treatment for clinically vulnerable populations. Idosos and individuals with cardiac comorbidities gain a viable alternative for controlling disabling crises. The leaflet approved by the Brazilian regulatory agency reflects this improved safety profile. Medical monitoring continues to be essential for the individualized assessment of each clinical case.
The development of safe therapies for the cardiovascular system represents a milestone in modern neurology. Migraines affect millions of Brazilians of working age and are among the main causes of absenteeism from work. Proper control of the condition improves quality of life and reduces indirect costs associated with frequent emergency room visits. The approval of Anvisa validates safety data collected during years of laboratory research and human testing.
Formatos Marketing and Regulatory Registration Details
The authorization granted by the health authority establishes strict parameters for the distribution of the product throughout the national territory. The official registration of the medicine is valid until May 2036. The technical documentation submitted by the manufacturer proved the chemical stability of the active ingredient and the adequacy of the manufacturing facilities. The analysis process followed the legal procedures required for innovative molecules.
The commercial presentations released to Brazilian pharmacies seek to meet different medical prescription profiles. Anvisa has approved the following packaging configurations for the domestic market:
- Cartelas containing 2 tablets for occasional use.
- Cartelas with 8 tablets for intermediate treatment.
- Cartelas with 16 tablets focused on preventive therapy.
- Dosagem standardized at 75 mg per orodispersible unit.
Apesar technical and sanitary release, the product does not yet have a confirmed date to hit the shelves. The pricing process for new medicines in Brasil goes through Câmara of Regulação of Mercado of Medicamentos. The government body evaluates the cost-effectiveness of the therapy before defining the maximum sales ceiling. Pfizer has not released an official logistics distribution schedule for healthcare retail chains.
Ensaios global clinical and results published in the journal The Lancet
The effectiveness of rimegepant hemisulfate sesquihydrate was confirmed through phase 3 clinical studies, the gold standard of scientific research. The detailed results were published in the prestigious medical journal The Lancet. The trial involved thousands of adults with a documented history of chronic and episodic migraines. The researchers adopted a double-blind and randomized method to ensure the impartiality of the data collected during the testing phase.
Study participants received a single 75 mg dose of the drug or a placebo pill at the time they had moderate to severe seizures. The primary assessment occurred exactly two hours after dose administration. The data revealed that 21% of patients treated with the active drug reported total absence of pain within the stipulated period. In the control group that took the placebo, the pain remission rate reached only 11%.
The research also measured the impact of medication on the disease’s secondary symptoms, often described as the most disabling. Extreme sensitivity to light, intolerance to sounds and nausea showed significant improvement. Cerca of 35% of individuals treated with rimegepant reported complete relief of these associated discomforts. The placebo group recorded a 27% improvement rate for the same clinical assessment criteria.
The tolerability profile of the tablet was favorable throughout the observation period. The most frequently reported adverse events were limited to mild episodes of nausea and isolated cases of urinary infection. Ambas occurrences had a low statistical incidence among volunteers. The team of scientists responsible for monitoring did not record any serious adverse events






